Interventional technology firm Medtronic has filed the final module of its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for its Talent abdominal stent graft system.
Talent is designed to treat dangerous bulges in the aorta, according to the Minneapolis-based company.
Related Reading
FDA clears Medtronic's biliary stent system, November 15, 2007
Medtronic nets CE Mark, October 23, 2007
Medtronic's Endeavor moves closer to clearance, October 11, 2007
Medtronic launches CareLink in Europe, August 30, 2007
Medtronic names new CEO, COO, August 24, 2007
Copyright © 2007 AuntMinnie.com